vs
ICU MEDICAL INC（ICUI）与朗美通（LITE）财务数据对比。点击上方公司名可切换其他公司
朗美通的季度营收约是ICU MEDICAL INC的1.2倍（$665.5M vs $540.7M），朗美通净利率更高（11.8% vs -2.9%，领先14.7%），朗美通同比增速更快（65.5% vs -14.1%），朗美通自由现金流更多（$43.1M vs $36.0M），过去两年朗美通的营收复合增速更高（34.8% vs -2.3%）
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
朗美通控股（Lumentum Holdings Inc.）是全球知名光电产品供应商，前身为美国捷迪讯（JDSU）旗下光电器件及激光业务板块，2015年8月随捷迪讯分拆独立运营，总部位于美国加利福尼亚州米尔皮塔斯，主营光通信网络设备、激光器、定制光学解决方案等多元产品。
ICUI vs LITE — 直观对比
营收规模更大
LITE
是对方的1.2倍
$540.7M
营收增速更快
LITE
高出79.6%
-14.1%
净利率更高
LITE
高出14.7%
-2.9%
自由现金流更多
LITE
多$7.1M
$36.0M
两年增速更快
LITE
近两年复合增速
-2.3%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $540.7M | $665.5M |
| 净利润 | $-15.7M | $78.2M |
| 毛利率 | 37.5% | 36.1% |
| 营业利润率 | 1.0% | 9.7% |
| 净利率 | -2.9% | 11.8% |
| 营收同比 | -14.1% | 65.5% |
| 净利润同比 | 34.0% | 228.4% |
| 每股收益（稀释后） | $-0.63 | $0.89 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICUILITE
| Q4 25 | $540.7M | $665.5M | ||
| Q3 25 | $537.0M | $533.8M | ||
| Q2 25 | $548.9M | $480.7M | ||
| Q1 25 | $604.7M | $425.2M | ||
| Q4 24 | $629.8M | $402.2M | ||
| Q3 24 | $589.1M | $336.9M | ||
| Q2 24 | $596.5M | $308.3M | ||
| Q1 24 | $566.7M | $366.5M |
净利润ICUILITE
| Q4 25 | $-15.7M | $78.2M | ||
| Q3 25 | $-3.4M | $4.2M | ||
| Q2 25 | $35.3M | $213.3M | ||
| Q1 25 | $-15.5M | $-44.1M | ||
| Q4 24 | $-23.8M | $-60.9M | ||
| Q3 24 | $-33.0M | $-82.4M | ||
| Q2 24 | $-21.4M | $-252.5M | ||
| Q1 24 | $-39.5M | $-127.0M |
毛利率ICUILITE
| Q4 25 | 37.5% | 36.1% | ||
| Q3 25 | 37.4% | 34.0% | ||
| Q2 25 | 37.9% | 33.3% | ||
| Q1 25 | 34.7% | 28.8% | ||
| Q4 24 | 36.1% | 24.8% | ||
| Q3 24 | 34.8% | 23.1% | ||
| Q2 24 | 34.8% | 16.6% | ||
| Q1 24 | 32.7% | 16.2% |
营业利润率ICUILITE
| Q4 25 | 1.0% | 9.7% | ||
| Q3 25 | 2.6% | 1.3% | ||
| Q2 25 | 1.9% | -1.7% | ||
| Q1 25 | 2.1% | -8.9% | ||
| Q4 24 | 6.0% | -12.8% | ||
| Q3 24 | 1.4% | -24.5% | ||
| Q2 24 | 1.3% | -43.3% | ||
| Q1 24 | -1.9% | -31.3% |
净利率ICUILITE
| Q4 25 | -2.9% | 11.8% | ||
| Q3 25 | -0.6% | 0.8% | ||
| Q2 25 | 6.4% | 44.4% | ||
| Q1 25 | -2.6% | -10.4% | ||
| Q4 24 | -3.8% | -15.1% | ||
| Q3 24 | -5.6% | -24.5% | ||
| Q2 24 | -3.6% | -81.9% | ||
| Q1 24 | -7.0% | -34.7% |
每股收益（稀释后）ICUILITE
| Q4 25 | $-0.63 | $0.89 | ||
| Q3 25 | $-0.14 | $0.05 | ||
| Q2 25 | $1.43 | $3.10 | ||
| Q1 25 | $-0.63 | $-0.64 | ||
| Q4 24 | $-0.97 | $-0.88 | ||
| Q3 24 | $-1.35 | $-1.21 | ||
| Q2 24 | $-0.88 | $-3.75 | ||
| Q1 24 | $-1.63 | $-1.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $1.2B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.1B | $846.6M |
| 总资产 | $4.1B | $4.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ICUILITE
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $877.1M | ||
| Q1 25 | — | $866.7M | ||
| Q4 24 | $308.6M | $896.7M | ||
| Q3 24 | $312.5M | $916.1M | ||
| Q2 24 | $302.6M | $887.0M | ||
| Q1 24 | $251.4M | $870.9M |
股东权益ICUILITE
| Q4 25 | $2.1B | $846.6M | ||
| Q3 25 | $2.1B | $780.8M | ||
| Q2 25 | $2.1B | $1.1B | ||
| Q1 25 | $2.0B | $879.5M | ||
| Q4 24 | $2.0B | $872.3M | ||
| Q3 24 | $2.0B | $895.9M | ||
| Q2 24 | $2.0B | $957.3M | ||
| Q1 24 | $2.1B | $1.2B |
总资产ICUILITE
| Q4 25 | $4.1B | $4.8B | ||
| Q3 25 | $4.1B | $4.6B | ||
| Q2 25 | $4.1B | $4.2B | ||
| Q1 25 | $4.2B | $4.0B | ||
| Q4 24 | $4.2B | $4.0B | ||
| Q3 24 | $4.3B | $4.0B | ||
| Q2 24 | $4.3B | $3.9B | ||
| Q1 24 | $4.3B | $4.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.6M | $126.7M |
| 自由现金流经营现金流 - 资本支出 | $36.0M | $43.1M |
| 自由现金流率自由现金流/营收 | 6.6% | 6.5% |
| 资本支出强度资本支出/营收 | 4.6% | 12.6% |
| 现金转化率经营现金流/净利润 | — | 1.62× |
| 过去12个月自由现金流最近4个季度 | $91.8M | $-29.5M |
8季度趋势，按日历期对齐
经营现金流ICUILITE
| Q4 25 | $60.6M | $126.7M | ||
| Q3 25 | $56.7M | $57.9M | ||
| Q2 25 | $11.2M | $64.0M | ||
| Q1 25 | $51.3M | $-1.6M | ||
| Q4 24 | $40.2M | $24.3M | ||
| Q3 24 | $36.1M | $39.6M | ||
| Q2 24 | $82.0M | $35.5M | ||
| Q1 24 | $45.8M | $-7.0M |
自由现金流ICUILITE
| Q4 25 | $36.0M | $43.1M | ||
| Q3 25 | $27.6M | $-18.3M | ||
| Q2 25 | $-8.5M | $10.1M | ||
| Q1 25 | $36.7M | $-64.4M | ||
| Q4 24 | $16.1M | $-15.9M | ||
| Q3 24 | $16.2M | $-34.5M | ||
| Q2 24 | $62.5M | $10.9M | ||
| Q1 24 | $29.9M | $-26.6M |
自由现金流率ICUILITE
| Q4 25 | 6.6% | 6.5% | ||
| Q3 25 | 5.1% | -3.4% | ||
| Q2 25 | -1.5% | 2.1% | ||
| Q1 25 | 6.1% | -15.1% | ||
| Q4 24 | 2.6% | -4.0% | ||
| Q3 24 | 2.7% | -10.2% | ||
| Q2 24 | 10.5% | 3.5% | ||
| Q1 24 | 5.3% | -7.3% |
资本支出强度ICUILITE
| Q4 25 | 4.6% | 12.6% | ||
| Q3 25 | 5.4% | 14.3% | ||
| Q2 25 | 3.6% | 11.2% | ||
| Q1 25 | 2.4% | 14.8% | ||
| Q4 24 | 3.8% | 10.0% | ||
| Q3 24 | 3.4% | 22.0% | ||
| Q2 24 | 3.3% | 8.0% | ||
| Q1 24 | 2.8% | 5.3% |
现金转化率ICUILITE
| Q4 25 | — | 1.62× | ||
| Q3 25 | — | 13.79× | ||
| Q2 25 | 0.32× | 0.30× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
LITE
| Components | $443.7M | 67% |
| Systems | $221.8M | 33% |
